Skip to content
OpenCapital
Get started

Dianthus Therapeutics DNTH Gain (Loss), Foreign Currency Transaction, before Tax

Gain (Loss), Foreign Currency Transaction, before Tax at other companies

Biogen logo
BiogenBIIB
——

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$4.51B+662%

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0×0.0×
Current ratio29.3×+13.3×

Where this comes from

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ForeignCurrencyTransactionGainLossBeforeTax.

The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dianthus Therapeutics's gain (loss), foreign currency transaction, before tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dianthus Therapeutics's gain (loss), foreign currency transaction, before tax?
Dianthus Therapeutics (DNTH) reported gain (loss), foreign currency transaction, before tax of -$15K in Q1 2026.
How has Dianthus Therapeutics's gain (loss), foreign currency transaction, before tax changed year-over-year?
Dianthus Therapeutics's gain (loss), foreign currency transaction, before tax increased by 31.8% year-over-year, from -$22K to -$15K.